{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:05:59Z","timestamp":1772179559943,"version":"3.50.1"},"reference-count":131,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T00:00:00Z","timestamp":1282003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer\u2019s disease (AD), Huntington\u2019s disease (HD), Parkinson\u2019s disease (PD) and vascular dementia (VD). Numerous studies have demonstrated an involvement of the cannabinoid system in neurotransmission, neuropathology and neurobiology of dementias. In addition, several candidate compounds have demonstrated efficacy in vitro. However, some of the substances produced inconclusive results in vivo. Therefore, only few trials have aimed to replicate the effects seen in animal studies in patients. Indeed, the literature on cannabinoid administration in patients is scarce. While preclinical findings suggest causal treatment strategies involving cannabinoids, clinical trials have only assessed the suitability of cannabinoid receptor agonists, antagonists and cannabidiol for the symptomatic treatment of dementia. Further research is needed, including in vivo models of dementia and human studies.<\/jats:p>","DOI":"10.3390\/ph3082689","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T11:36:41Z","timestamp":1282045001000},"page":"2689-2708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cannabinoids and Dementia: A Review of Clinical and Preclinical Data"],"prefix":"10.3390","volume":"3","author":[{"given":"Sebastian","family":"Walther","sequence":"first","affiliation":[{"name":"University Hospital of Psychiatry, Bolligenstrasse 111, 3000 Bern 60, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Halpern","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry, Bolligenstrasse 111, 3000 Bern 60, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2010,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: A delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in parkinson's disease: A community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1474-4422(05)70221-0","article-title":"Poststroke dementia","volume":"4","author":"Leys","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(10)70238-3","article-title":"Huntington's disease: Pathogenesis to animal models","volume":"62","author":"Kumar","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer's disease: Strategies for disease modification","volume":"9","author":"Citron","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cdna","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1006\/nbdi.1998.0229","article-title":"The functional neuroanatomy of brain cannabinoid receptors","volume":"5","author":"Breivogel","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bjp.0707446","article-title":"Alzheimer's disease; taking the edge off with cannabinoids?","volume":"152","author":"Campbell","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of pharmacology. Xxvii. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2004.07.030","article-title":"Cannabinoid physiology and pharmacology: 30 years of progress","volume":"47","author":"Howlett","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1055\/s-0029-1216346","article-title":"Neurobiology and systems physiology of the endocannabinoid system","volume":"42","author":"Wegener","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.1063545","article-title":"Endocannabinoid signaling in the brain","volume":"296","author":"Wilson","year":"2002","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/372686a0","article-title":"Formation and inactivation of endogenous cannabinoid anandamide in central neurons","volume":"372","author":"Fontana","year":"1994","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","article-title":"Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain","volume":"77","author":"Glass","year":"1997","journal-title":"Neuroscience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1523\/JNEUROSCI.21-23-09506.2001","article-title":"Distribution of cb1 cannabinoid receptors in the amygdala and their role in the control of gabaergic transmission","volume":"21","author":"Katona","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1523\/JNEUROSCI.19-11-04544.1999","article-title":"Presynaptically located cb1 cannabinoid receptors regulate gaba release from axon terminals of specific hippocampal interneurons","volume":"19","author":"Katona","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2174\/138955709787847921","article-title":"Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration","volume":"9","author":"Basavarajappa","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12035-007-8006-8","article-title":"The endocannabinoid system and alzheimer's disease","volume":"36","author":"Benito","year":"2007","journal-title":"Mol. Neurobiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/138955709788167628","article-title":"Cannabinoid system in neurodegeneration: New perspectives in alzheimer's disease","volume":"9","author":"Campillo","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2174\/138161208785740054","article-title":"Role of cannabinoids and endocannabinoids in cerebral ischemia","volume":"14","author":"Hillard","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1568007033482751","article-title":"The endocannabinoid system and huntington's disease","volume":"2","year":"2003","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuron.2004.09.010","article-title":"Deciphering the molecular basis of memory failure in alzheimer's disease","volume":"44","author":"Walsh","year":"2004","journal-title":"Neuron"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1474-4422(04)00707-0","article-title":"Alzheimer's disease: The two-hit hypothesis","volume":"3","author":"Zhu","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00065.x","article-title":"Cannabidiol: A promising drug for neurodegenerative disorders?","volume":"15","author":"Iuvone","year":"2009","journal-title":"CNS Neurosci. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.neurobiolaging.2007.04.028","article-title":"Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats","volume":"29","author":"Marchalant","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.neuroscience.2006.11.016","article-title":"Anti-inflammatory property of the cannabinoid agonist win-55212-2 in a rodent model of chronic brain inflammation","volume":"144","author":"Marchalant","year":"2007","journal-title":"Neuroscience"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1523\/JNEUROSCI.0309-06.2006","article-title":"Molecular composition of the endocannabinoid system at glutamatergic synapses","volume":"26","author":"Katona","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1523\/JNEUROSCI.21-17-06480.2001","article-title":"Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity","volume":"21","author":"Brown","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0306-4522(94)90511-8","article-title":"Cannabinoid receptor binding and messenger rna expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and alzheimer's brains","volume":"63","author":"Westlake","year":"1994","journal-title":"Neuroscience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid cb2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1523\/JNEUROSCI.16-14-04322.1996","article-title":"Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures","volume":"16","author":"Shen","year":"1996","journal-title":"J. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/mol.54.3.459","article-title":"Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity","volume":"54","author":"Shen","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"Cb1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1046\/j.1471-4159.2001.00542.x","article-title":"Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration","volume":"78","author":"Hansen","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1523\/JNEUROSCI.21-17-06475.2001","article-title":"Neuroprotection by delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity","volume":"21","author":"Veldhuis","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.1523\/JNEUROSCI.21-22-08765.2001","article-title":"Exogenous anandamide protects rat brain against acute neuronal injury in vivo","volume":"21","author":"Veldhuis","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3940(02)00936-9","article-title":"Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide","volume":"332","author":"Milton","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neulet.2006.06.012","article-title":"Cb1 receptor selective activation inhibits beta-amyloid-induced inos protein expression in c6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons","volume":"404","author":"Esposito","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1460-9568.2004.03285.x","article-title":"Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity","volume":"19","author":"Khaspekov","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1523\/JNEUROSCI.23-16-06470.2003","article-title":"Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia","volume":"23","author":"Pinteaux","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-2007-12402","article-title":"Comparison analysis of gene expression patterns between sporadic alzheimer's and parkinson's disease","volume":"12","author":"Grunblatt","year":"2007","journal-title":"J. Alzheimers Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (cb2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J. Neuroinflammation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1471-4159.2005.03380.x","article-title":"Modulation of the cannabinoid cb2 receptor in microglial cells in response to inflammatory stimuli","volume":"95","author":"Maresz","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","article-title":"The activation of cannabinoid cb2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages","volume":"1283","author":"Tolon","year":"2009","journal-title":"Brain Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and alzheimer's disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on beta-amyloid-induced toxicity in pc12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","article-title":"The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through wnt\/beta-catenin pathway rescue in pc12 cells","volume":"84","author":"Esposito","year":"2006","journal-title":"J. Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","article-title":"Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated pc12 neurons through p38 map kinase and nf-kappab involvement","volume":"399","author":"Esposito","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing il-1beta and inos expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/00001756-200410250-00016","article-title":"Cannabidiol prevents infarction via the non-cb1 cannabinoid receptor mechanism","volume":"15","author":"Hayakawa","year":"2004","journal-title":"Neuroreport"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1161\/01.STR.0000079817.68944.1E","article-title":"Drug-induced hypothermia reduces ischemic damage: Effects of the cannabinoid hu-210","volume":"34","author":"Leker","year":"2003","journal-title":"Stroke"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-8993(99)02422-1","article-title":"The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat","volume":"857","author":"Louw","year":"2000","journal-title":"Brain Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0006-8993(03)03376-6","article-title":"Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist bay 38-7271","volume":"989","author":"Mauler","year":"2003","journal-title":"Brain Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1523\/JNEUROSCI.19-08-02987.1999","article-title":"Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures","volume":"19","author":"Nagayama","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1523\/JNEUROSCI.22-22-09771.2002","article-title":"Increased severity of stroke in cb1 cannabinoid receptor knock-out mice","volume":"22","author":"Jin","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.bjp.0707514","article-title":"Delta9-tetrahydrocannabinol (thc) and am 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors","volume":"152","author":"Zani","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-4658.2008.06765.x","article-title":"Post-ischemic brain damage: The endocannabinoid system in the mechanisms of neuronal death","volume":"276","author":"Mannaioni","year":"2009","journal-title":"FEBS J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00004647-200405000-00011","article-title":"The \"Dark side\" Of endocannabinoids: A neurotoxic role for anandamide","volume":"24","author":"Cernak","year":"2004","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/STROKEAHA.109.559880","article-title":"Epidemiological studies of the effect of stroke on incident dementia: A systematic review","volume":"41","author":"Savva","year":"2010","journal-title":"Stroke"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","article-title":"Loss of cannabinoid receptors in the substantia nigra in huntington's disease","volume":"56","author":"Glass","year":"1993","journal-title":"Neuroscience"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and gaba(a) receptor alterations in the human basal ganglia in huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ana.410360406","article-title":"Selective vulnerability in huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus","volume":"36","author":"Richfield","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchemneu.2009.02.001","article-title":"Cannabinoid (cb(1)), gaba(a) and gaba(b) receptor subunit changes in the globus pallidus in huntington's disease","volume":"37","author":"Allen","year":"2009","journal-title":"J. Chem. Neuroanat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.biopsych.2005.03.008","article-title":"Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of r6\/2 huntington's disease mice","volume":"57","author":"Centonze","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","article-title":"Cannabinoid receptor messenger rna levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic huntington's disease mice","volume":"98","author":"Robertson","year":"2000","journal-title":"Neuroscience"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1111\/j.1432-1033.2004.04460.x","article-title":"Structure, expression and regulation of the cannabinoid receptor gene (cb1) in huntington's disease transgenic mice","volume":"271","author":"McCaw","year":"2004","journal-title":"Eur. J. Biochem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","article-title":"Loss of mrna levels, binding and activation of gtp-binding proteins for cannabinoid cb1 receptors in the basal ganglia of a transgenic model of huntington's disease","volume":"929","author":"Berrendero","year":"2002","journal-title":"Brain Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid cb1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/00001756-200107200-00017","article-title":"Changes in endocannabinoid transmission in the basal ganglia in a rat model of huntington's disease","volume":"12","author":"Fezza","year":"2001","journal-title":"Neuroreport"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","article-title":"A cell-based screen for drugs to treat huntington's disease","volume":"16","author":"Aiken","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","article-title":"Effects of cannabinoids in the rat model of huntington's disease generated by an intrastriatal injection of malonate","volume":"14","author":"Bizat","year":"2003","journal-title":"Neuroreport"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neuroscience.2007.11.044","article-title":"Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions","volume":"152","author":"Zuccato","year":"2008","journal-title":"Neuroscience"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial cb2 cannabinoid receptors are neuroprotective in huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in huntington's disease: A pet study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic huntington's disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.brainres.2005.05.024","article-title":"Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of huntington's disease","volume":"1050","author":"Urbani","year":"2005","journal-title":"Brain Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","article-title":"Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of huntington's disease","volume":"84","author":"Makriyannis","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/syn.10054","article-title":"Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of huntington's disease","volume":"44","author":"Hansen","year":"2002","journal-title":"Synapse"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jchemneu.2006.01.005","article-title":"A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and huntington's disease human brain","volume":"31","author":"Curtis","year":"2006","journal-title":"J. Chem. Neuroanat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neures.2008.04.011","article-title":"The cannabinoid cp55,940 prolongs survival and improves locomotor activity in drosophila melanogaster against paraquat: Implications in parkinson's disease","volume":"61","year":"2008","journal-title":"Neurosci. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to parkinson's disease","volume":"19","author":"Ramos","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Gonzalez","year":"2007","journal-title":"Brain Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","article-title":"Win55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson's disease","volume":"29","author":"Price","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/exnr.1997.6645","article-title":"The cannabinoid receptor agonist win 55, 212-2 reduces d2, but not d1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of parkinson's disease","volume":"148","author":"Maneuf","year":"1997","journal-title":"Exp. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fasebj.14.10.1432","article-title":"Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of parkinson's disease","volume":"14","author":"Hill","year":"2000","journal-title":"FASEB J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1006\/exnr.2001.7649","article-title":"Striatal cannabinoid cb1 receptor mrna expression is decreased in the reserpine-treated rat model of parkinson's disease","volume":"169","author":"Silverdale","year":"2001","journal-title":"Exp. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1152\/jn.2001.85.1.468","article-title":"Cb1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum","volume":"85","author":"Gerdeman","year":"2001","journal-title":"J. Neurophysiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbr.2009.04.035","article-title":"The cb(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of parkinson's disease","volume":"203","author":"Kelsey","year":"2009","journal-title":"Behav. Brain Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.107.125666","article-title":"Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys","volume":"323","author":"Cao","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nbd.2004.10.015","article-title":"Cannabinoid cb1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism","volume":"18","author":"Caraballo","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130100728","article-title":"Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (mptp)-treated non-human primates","volume":"156","author":"Meschler","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.euroneuro.2007.11.003","article-title":"Therapeutic effects of delta9-thc and modafinil in a marmoset parkinson model","volume":"18","author":"Vanwersch","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the mptp-lesioned nonhuman primate model of parkinson's disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0773.2003.930202.x","article-title":"The cb1 cannabinoid receptor agonist, hu-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats","volume":"93","author":"Melamed","year":"2003","journal-title":"Pharmacol. Toxicol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuint.2008.10.007","article-title":"Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist win55,212-2","volume":"54","author":"Morgese","year":"2009","journal-title":"Neurochem. Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11910-009-0065-y","article-title":"Vascular dementia: A review of recent evidence for prevention and treatment","volume":"9","author":"Kirshner","year":"2009","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Krishnan, S., Cairns, R., and Howard, R. (2009). Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev., CD007204.","DOI":"10.1002\/14651858.CD007204.pub2"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with alzheimer's disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/gps.1828","article-title":"The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation","volume":"23","author":"Passmore","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1471-4159.2009.06025.x","article-title":"Lack of cb1 receptor activity impairs serotonergic negative feedback","volume":"109","author":"Aso","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","article-title":"Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex","volume":"27","author":"Bambico","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nn.2494","article-title":"Bimodal control of stimulated food intake by the endocannabinoid system","volume":"13","author":"Bellocchio","year":"2010","journal-title":"Nat. Neurosci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.pnpbp.2008.04.008","article-title":"The role of the cb1 receptor in the regulation of sleep","volume":"32","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/sleep\/26.8.943","article-title":"Anandamide enhances extracellular levels of adenosine and induces sleep: An in vivo microdialysis study","volume":"26","author":"Sanchez","year":"2003","journal-title":"Sleep"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Staekenborg, S.S., Su, T., van Straaten, E.C., Lane, R., Scheltens, P., Barkhof, F., and van der Flier, W.M. (2009). Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease. J. Neurol. Neurosurg. Psychiatry.","DOI":"10.1136\/jnnp.2009.187500"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.phrs.2007.09.003","article-title":"Enhancement of endocannabinoid signaling and the pharmacotherapy of depression","volume":"56","author":"Mangieri","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in huntington's disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J. Neuropsychiatry. Clin. Neurosci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in huntington's disease","volume":"14","author":"Schneider","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/mds.20111","article-title":"Survey on cannabis use in parkinson's disease: Subjective improvement of motor symptoms","volume":"19","author":"Venderova","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00207458608985678","article-title":"Open label evaluation of cannabidiol in dystonic movement disorders","volume":"30","author":"Consroe","year":"1986","journal-title":"Int. J. Neurosci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in parkinson's disease: A pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in parkinson disease: A randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin b, neurotensin, and cannabinoid receptor antagonists and parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in parkinson's disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/8\/2689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:03:10Z","timestamp":1760220190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/8\/2689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,17]]},"references-count":131,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,8]]}},"alternative-id":["ph3082689"],"URL":"https:\/\/doi.org\/10.3390\/ph3082689","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,17]]}}}